SAB Biotherapeutics SABS Income Statement (2020-2026)

NASDAQ SABS
$3.11 +0.04 (+1.30%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

SAB Biotherapeutics Quarterly Income Statement

Periods 24 quarters
Latest Sep 2026

SAB Biotherapeutics reported revenue of $1.61M and net income of -$23.67M for the quarter ended Sep 2026, up 162.7% year over year. This income statement covers 24 quarters of results from Dec 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
11.06M11.80M6.35M3.59M2.16M0.58M0.09M1.27M0.31M0.94M0.26M0.11M0.61M1.61M
Operating items
Research & DevelopmentR&D
10.65M13.32M8.58M7.35M7.14M4.54M3.66M4.02M4.30M8.15M6.82M7.83M7.65M7.66M7.00M8.97M10.73M13.40M16.17M18.08M
Selling, General & AdministrativeSG&A
7.75M5.19M4.31M4.04M2.88M3.45M2.90M2.57M14.88M4.19M3.64M3.48M2.47M3.11M2.74M3.71M5.04M6.60M7.21M7.82M
Other Operating ExpensesOther Opex
Operating ExpensesOpex
18.40M18.51M12.89M11.40M10.02M7.98M6.56M6.59M19.18M12.34M10.46M11.31M10.12M10.77M9.73M12.68M15.77M20.00M23.38M25.90M
Operating IncomeOp. Inc
-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M-23.38M-25.90M
Non-operating items
Non Operating Interest Expenses
0.07M0.07M0.07M0.07M0.09M0.09M0.08M0.07M0.08M0.08M0.09M0.08M0.07M0.07M0.06M0.04M0.06M0.06M0.06M
Interest & Investment IncomeInt & Inv Inc
0.01M0.01M0.02M0.02M0.03M0.06M0.03M0.01M0.48M0.50M0.37M0.28M0.14M0.06M0.01M0.66M0.70M1.05M1.71M
Other Non Operating IncomeOther Non Op Inc.
4.15M-7.85M-1.73M-0.78M0.00M-0.08M0.36M-0.08M5.06M-4.99M-1.85M0.75M3.16M-4.49M0.92M-60.83M4.78M1.11M1.46M-1.31M
Non Operating IncomeNon Op. Inc.
-4.21M7.79M1.67M0.73M0.01M0.05M-0.40M0.22M-3.98M6.36M2.87M0.96M-1.39M5.58M-0.38M58.12M-1.09M1.13M0.89M3.60M
Net income details
EBIT
-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M-23.38M-25.90M
EBT
-11.55M1.08M-4.87M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.94M-10.78M-9.78M-12.07M-15.13M-19.01M-21.73M-25.90M
Tax ProvisionsTaxes
0.09M-0.09M
Income After Tax
-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.94M-10.78M-9.78M-12.07M-15.13M-19.01M-21.73M-25.90M
Income from Continuing OperationsIncome (Continuing)
-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.94M-10.78M-9.78M-12.07M-15.13M-19.01M-21.73M-25.90M
Consolidated Net IncomeConsol Net Inc.
-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.83M-5.12M-7.30M-10.27M-11.58M-5.17M-10.02M45.53M-16.75M-19.28M-23.20M-23.67M
Income towards Parent CompanyParent Net Inc
-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M45.45M-16.86M-18.87M-22.49M-22.30M
Net Income towards Common StockholdersNet Income
-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M45.45M-16.86M-18.87M-22.49M-22.30M
Additional items
EPS (Basic)
-4.230.23-1.11-1.64-1.81-1.46-1.36-0.97-4.14-0.54-0.79-1.12-1.23-0.56-1.094.26-0.87-0.35-0.28-0.24
EPS (Diluted)
-4.230.22-1.11-1.64-1.81-1.46-1.36-0.97-4.14-0.54-0.79-1.12-1.23-0.56-1.090.58-0.27-0.35-0.28-0.29
Shares Outstanding
2.73M4.31M4.30M4.30M4.35M5.04M5.04M5.24M5.52M9.24M9.26M9.26M9.26M9.29M9.29M10.66M19.31M53.56M79.75M93.24M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
2.73M4.58M4.30M4.30M4.35M5.04M5.04M5.24M5.52M9.24M9.26M9.26M9.26M9.29M9.29M77.86M61.34M53.56M79.75M75.70M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
2.73M4.30M4.30M4.30M5.04M5.09M5.23M5.23M5.52M9.23M9.23M9.23M9.29M9.35M9.29M10.66M19.31M53.56M83.49M91.14M
EBITDA
-6.68M-6.03M-5.76M-6.89M-6.91M-6.48M-5.55M-4.30M-17.87M-9.37M-9.18M-10.39M-9.21M-9.95M-8.91M-11.96M-15.04M-19.24M-22.56M-25.08M
Interest ExpensesInt Expense
0.07M0.07M0.07M0.07M0.09M0.09M0.08M0.07M0.08M0.08M0.09M0.08M0.07M0.07M0.06M0.04M0.06M0.06M0.06M
Tax Rate
8.56%

SAB Biotherapeutics Income Statement API

Pull SAB Biotherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SABS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY